{"id":14637,"date":"2025-07-16T14:48:43","date_gmt":"2025-07-16T14:48:43","guid":{"rendered":"https:\/\/www.rawoodfoundation.org\/?p=14637"},"modified":"2025-10-29T13:00:38","modified_gmt":"2025-10-29T13:00:38","slug":"nuevas-fronteras-en-la-investigacion-de-la-obesidad-hipotalamica","status":"publish","type":"post","link":"https:\/\/www.rawoodfoundation.org\/es\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/","title":{"rendered":"Nuevas fronteras en la investigaci\u00f3n de la obesidad hipotal\u00e1mica"},"content":{"rendered":"

Los ensayos cl\u00ednicos actuales y los nuevos datos ofrecen esperanzas para la HO<\/h2>\n\n\n\n

Para los supervivientes de tumores hipot\u00e1lamo-hipofisarios, especialmente de craneofaringioma, la obesidad hipotal\u00e1mica (HO) es uno de los efectos a largo plazo m\u00e1s dif\u00edciles y que m\u00e1s alteran la vida. No se debe a un estilo de vida, sino a da\u00f1os en la parte del cerebro responsable de regular el hambre, el equilibrio energ\u00e9tico y el metabolismo. Las estrategias convencionales de dieta y ejercicio suelen ser ineficaces, lo que deja a los pacientes con pocas opciones y una sensaci\u00f3n de desesperanza.<\/p>\n\n\n\n

Eso est\u00e1 empezando a cambiar.<\/strong><\/p>\n\n\n\n

Los investigadores y desarrolladores farmac\u00e9uticos se centran ahora en la HO, desarrollando f\u00e1rmacos dirigidos Tratamientos de la obesidad hipotal\u00e1mica<\/a> que reflejan la biolog\u00eda \u00fanica y los retos de esta enfermedad. A continuaci\u00f3n se ofrece un resumen de los ensayos cl\u00ednicos que actualmente est\u00e1n reclutando participantes, as\u00ed como de los que han completado fases clave y publicado datos. Estos estudios est\u00e1n dando forma al futuro de la atenci\u00f3n de la HO y pronto podr\u00edan aportar terapias muy necesarias a pacientes y familias que durante mucho tiempo han estado desatendidos.<\/p>\n\n\n\n

Reclutamiento activo de ensayos<\/strong><\/h3>\n\n\n\n

Fentermina\/Topiramato para la obesidad hipotal\u00e1mica<\/strong>
Este estudio de fase 2 investiga el uso de un f\u00e1rmaco combinado -la fentermina, un supresor del apetito, y el topiramato, que influye en el ansia y el consumo de energ\u00eda- ya aprobado por la FDA para la obesidad general. El ensayo eval\u00faa su seguridad y eficacia en personas diagnosticadas espec\u00edficamente de obesidad hipotal\u00e1mica, a menudo tras el tratamiento de tumores cerebrales. Este estudio refleja el creciente reconocimiento de que la HO requiere un enfoque cl\u00ednico diferente.
M\u00e1s informaci\u00f3n:<\/strong> Enlace de prueba<\/a><\/p>\n\n\n\n

RM-718 para la obesidad hipotal\u00e1mica
<\/strong>RM-718 es un agonista del receptor de melanocortina 4 (MC4R) de nueva generaci\u00f3n dise\u00f1ado para reducir el hambre y favorecer la regulaci\u00f3n del peso sin aumentar la presi\u00f3n arterial ni la frecuencia card\u00edaca. Este estudio de fase 1 se centra en determinar la dosis segura y los efectos iniciales en individuos con HO. Este ensayo representa un importante paso adelante para una comunidad que hist\u00f3ricamente ha carecido de opciones farmacol\u00f3gicas basadas en la evidencia.
M\u00e1s informaci\u00f3n:<\/strong> Enlace de prueba<\/a><\/p>\n\n\n\n

Tirzepatida para la p\u00e9rdida de peso en el s\u00edndrome de Prader-Willi, la obesidad hipotal\u00e1mica y la obesidad general\u00a0<\/strong><\/strong>
En este ensayo se est\u00e1 investigando la tirzepatida, un agonista dual de los receptores GIP\/GLP-1, ya aprobado para la diabetes de tipo 2 y la obesidad, en el SPW y la HO. Su mecanismo tambi\u00e9n puede ser prometedor para las personas con HO. Los s\u00edntomas, incluida la hiperfagia y la desregulaci\u00f3n metab\u00f3lica, hacen que este ensayo sea muy relevante para la comunidad m\u00e1s amplia de supervivientes de tumores cerebrales hipotal\u00e1mico-hipofisarios.
M\u00e1s informaci\u00f3n<\/strong>: Enlace de prueba<\/a><\/p>\n\n\n\n

Ensayos con inscripci\u00f3n finalizada y datos publicados<\/strong><\/h2>\n\n\n\n

Setmelanotida (IMCIVREE\u00ae)<\/strong>
La setmelanotida, un agonista de MC4R, ya ha mostrado beneficios cl\u00ednicos en s\u00edndromes gen\u00e9ticos de obesidad poco frecuentes y se ha probado en 120 pacientes, el mayor ensayo controlado aleatorizado en HO hasta la fecha. Recientemente, en ENDO 2025, se han publicado datos que muestran reducciones significativas del IMC en todos los grupos de edad. Estos resultados son alentadores tanto para los pacientes como para los m\u00e9dicos.
Comunicado de prensa: Leer el anuncio<\/a><\/p>\n\n\n\n

Bivamelagon (LB54640)
<\/strong>Bivamelagon es un agonista oral de MC4R que ha concluido recientemente los ensayos de fase 2. Este f\u00e1rmaco ofrece la opci\u00f3n de tomar un comprimido una vez al d\u00eda, lo que puede reducir la carga del tratamiento y mejorar la accesibilidad. En el ensayo doble ciego, de cuatro brazos y controlado con placebo, de 14 semanas de duraci\u00f3n, el bivamelag\u00f3n logr\u00f3 reducciones estad\u00edsticamente significativas y cl\u00ednicamente relevantes del \u00edndice de masa corporal (IMC), en consonancia con las reducciones del IMC conseguidas con el tratamiento con setmelanotida. 
Comunicado de prensa: Leer el anuncio<\/a><\/p>\n\n\n\n

Por qu\u00e9 es importante<\/strong><\/h3>\n\n\n\n

La investigaci\u00f3n cl\u00ednica es un paso vital hacia la transformaci\u00f3n del panorama asistencial de la obesidad hipotal\u00e1mica. Estos ensayos no s\u00f3lo representan un avance cient\u00edfico, sino tambi\u00e9n una esperanza. La disponibilidad de nuevas terapias basadas en la biolog\u00eda del cerebro podr\u00eda cambiar la vida de las familias que se enfrentan a un trastorno que ha sido incomprendido y desatendido.<\/p>\n\n\n\n

En la Fundaci\u00f3n Raymond A. Wood seguimos comprometidos con la defensa de una investigaci\u00f3n que refleje las experiencias vividas por nuestra comunidad. Seguiremos compartiendo informaci\u00f3n actualizada sobre estos y otros estudios a medida que dispongamos de datos.<\/p>\n\n\n\n

Si desea m\u00e1s informaci\u00f3n u orientaci\u00f3n sobre ensayos cl\u00ednicos, visite nuestro buscador de ensayos cl\u00ednicos<\/a> <\/a>o \u00fanase a nosotros en noviembre para nuestro Conferencia familiar sobre tumores cerebrales hipofisarios<\/a> en Filadelfia.<\/p>","protected":false},"excerpt":{"rendered":"

Los ensayos cl\u00ednicos actuales y los nuevos datos publicados ofrecen esperanzas para la HO Para los supervivientes de ... Seguir leyendo<\/a><\/p>","protected":false},"author":6,"featured_media":14638,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[29,20],"tags":[],"class_list":["post-14637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hypothalamic-obesity","category-latest-research","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33","no-featured-image-padding"],"acf":[],"yoast_head":"\nNew Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rawoodfoundation.org\/es\/2025\/07\/16\/nuevas-fronteras-en-la-investigacion-de-la-obesidad-hipotalamica\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation\" \/>\n<meta property=\"og:description\" content=\"Current Clinical Trials and Newly Released Data Offering Hope for HO For survivors of hypothalamic-pituitary ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rawoodfoundation.org\/es\/2025\/07\/16\/nuevas-fronteras-en-la-investigacion-de-la-obesidad-hipotalamica\/\" \/>\n<meta property=\"og:site_name\" content=\"Raymond A. Wood Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/rawoodfoundation\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T14:48:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T13:00:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"477\" \/>\n\t<meta property=\"og:image:height\" content=\"326\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"RAWF\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@rawoodfound\" \/>\n<meta name=\"twitter:site\" content=\"@rawoodfound\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"RAWF\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\"},\"author\":{\"name\":\"RAWF\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/person\\\/12e3ee04f1646efc9cbbc13eb127f3b4\"},\"headline\":\"New Frontiers in Hypothalamic Obesity Research\",\"datePublished\":\"2025-07-16T14:48:43+00:00\",\"dateModified\":\"2025-10-29T13:00:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\"},\"wordCount\":604,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"articleSection\":[\"Hypothalamic Obesity\",\"Latest Research\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\",\"name\":\"New Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"datePublished\":\"2025-07-16T14:48:43+00:00\",\"dateModified\":\"2025-10-29T13:00:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"contentUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"width\":477,\"height\":326,\"caption\":\"Image of medications with title New Frontiers in Hypothalamic Obesity: Clinical Trials Offering Hope\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Frontiers in Hypothalamic Obesity Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#website\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/\",\"name\":\"Raymond A. Wood Foundation\",\"description\":\"The mission of the RAWF is to provide quality of life support for childhood brain tumor survivors and their families.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#organization\",\"name\":\"Raymond A. Wood Foundation\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Raymond-A-Wood-Foundation-logo.webp\",\"contentUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Raymond-A-Wood-Foundation-logo.webp\",\"width\":470,\"height\":128,\"caption\":\"Raymond A. Wood Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/rawoodfoundation\",\"https:\\\/\\\/x.com\\\/rawoodfound\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/person\\\/12e3ee04f1646efc9cbbc13eb127f3b4\",\"name\":\"RAWF\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/es\\\/author\\\/rawf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuevas fronteras en la investigaci\u00f3n de la obesidad hipotal\u00e1mica - Fundaci\u00f3n Raymond A. Wood","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rawoodfoundation.org\/es\/2025\/07\/16\/nuevas-fronteras-en-la-investigacion-de-la-obesidad-hipotalamica\/","og_locale":"es_MX","og_type":"article","og_title":"New Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation","og_description":"Current Clinical Trials and Newly Released Data Offering Hope for HO For survivors of hypothalamic-pituitary ... Read more","og_url":"https:\/\/www.rawoodfoundation.org\/es\/2025\/07\/16\/nuevas-fronteras-en-la-investigacion-de-la-obesidad-hipotalamica\/","og_site_name":"Raymond A. Wood Foundation","article_publisher":"https:\/\/www.facebook.com\/rawoodfoundation","article_published_time":"2025-07-16T14:48:43+00:00","article_modified_time":"2025-10-29T13:00:38+00:00","og_image":[{"width":477,"height":326,"url":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","type":"image\/png"}],"author":"RAWF","twitter_card":"summary_large_image","twitter_creator":"@rawoodfound","twitter_site":"@rawoodfound","twitter_misc":{"Escrito por":"RAWF","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#article","isPartOf":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/"},"author":{"name":"RAWF","@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/person\/12e3ee04f1646efc9cbbc13eb127f3b4"},"headline":"New Frontiers in Hypothalamic Obesity Research","datePublished":"2025-07-16T14:48:43+00:00","dateModified":"2025-10-29T13:00:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/"},"wordCount":604,"publisher":{"@id":"https:\/\/www.rawoodfoundation.org\/#organization"},"image":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","articleSection":["Hypothalamic Obesity","Latest Research"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/","url":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/","name":"Nuevas fronteras en la investigaci\u00f3n de la obesidad hipotal\u00e1mica - Fundaci\u00f3n Raymond A. Wood","isPartOf":{"@id":"https:\/\/www.rawoodfoundation.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage"},"image":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","datePublished":"2025-07-16T14:48:43+00:00","dateModified":"2025-10-29T13:00:38+00:00","breadcrumb":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage","url":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","contentUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","width":477,"height":326,"caption":"Image of medications with title New Frontiers in Hypothalamic Obesity: Clinical Trials Offering Hope"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rawoodfoundation.org\/"},{"@type":"ListItem","position":2,"name":"New Frontiers in Hypothalamic Obesity Research"}]},{"@type":"WebSite","@id":"https:\/\/www.rawoodfoundation.org\/#website","url":"https:\/\/www.rawoodfoundation.org\/","name":"Fundaci\u00f3n Raymond A. Wood","description":"La misi\u00f3n de la RAWF es proporcionar apoyo a la calidad de vida de los supervivientes de tumores cerebrales infantiles y sus familias.","publisher":{"@id":"https:\/\/www.rawoodfoundation.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rawoodfoundation.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.rawoodfoundation.org\/#organization","name":"Fundaci\u00f3n Raymond A. Wood","url":"https:\/\/www.rawoodfoundation.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2023\/07\/Raymond-A-Wood-Foundation-logo.webp","contentUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2023\/07\/Raymond-A-Wood-Foundation-logo.webp","width":470,"height":128,"caption":"Raymond A. Wood Foundation"},"image":{"@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/rawoodfoundation","https:\/\/x.com\/rawoodfound"]},{"@type":"Person","@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/person\/12e3ee04f1646efc9cbbc13eb127f3b4","name":"RAWF","url":"https:\/\/www.rawoodfoundation.org\/es\/author\/rawf\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/posts\/14637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/comments?post=14637"}],"version-history":[{"count":5,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/posts\/14637\/revisions"}],"predecessor-version":[{"id":17619,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/posts\/14637\/revisions\/17619"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/media\/14638"}],"wp:attachment":[{"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/media?parent=14637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/categories?post=14637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/es\/wp-json\/wp\/v2\/tags?post=14637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}